tiprankstipranks
Advertisement
Advertisement

VERA Stock Latest News

Buy Rating Reiterated on Vera as Atacicept Data Strengthens Case and Shares Trade Below Unchanged $66 Price Target
RatingsBuy Rating Reiterated on Vera as Atacicept Data Strengthens Case and Shares Trade Below Unchanged $66 Price Target
7d ago
VERA
Vera Therapeutics price target lowered to $90 from $125 at H.C. Wainwright
PremiumThe Fly
Vera Therapeutics price target lowered to $90 from $125 at H.C. Wainwright
7d ago
VERA
Analyst Maintains Buy on Vera Therapeutics, Cutting Trutakna Price Target to $90 Amid Rising IgAN Competition
PremiumRatings
Analyst Maintains Buy on Vera Therapeutics, Cutting Trutakna Price Target to $90 Amid Rising IgAN Competition
12d ago
VERA
Analyst Sees Vera Well Positioned for Trutakna IgAN Launch, Sustained Uptake and Long‑Term Value Creation
PremiumRatings
Analyst Sees Vera Well Positioned for Trutakna IgAN Launch, Sustained Uptake and Long‑Term Value Creation
12d ago
VERA
Vera Therapeutics price target raised to $84 from $78 at Raymond James
PremiumThe Fly
Vera Therapeutics price target raised to $84 from $78 at Raymond James
13d ago
VERA
Vera Therapeutics price target lowered to $34 from $43 at Wedbush
PremiumThe FlyVera Therapeutics price target lowered to $34 from $43 at Wedbush
13d ago
VERA
Vera Therapeutics price target lowered to $66 from $70 at BofA
Premium
The Fly
Vera Therapeutics price target lowered to $66 from $70 at BofA
13d ago
VERA
Analyst Reiterates Buy on Vera as Trutakna Launch and IgAN Pipeline Progress Support Maintained $90 Price Target
Premium
Ratings
Analyst Reiterates Buy on Vera as Trutakna Launch and IgAN Pipeline Progress Support Maintained $90 Price Target
13d ago
VERA
Vera Therapeutics reports Q3 EPS ($1.52), consensus ($1.59)
PremiumThe Fly
Vera Therapeutics reports Q3 EPS ($1.52), consensus ($1.59)
13d ago
VERA
Vera Therapeutics Announces New Chief Regulatory Officer
PremiumCompany Announcements
Vera Therapeutics Announces New Chief Regulatory Officer
2M ago
8K
VERA
Vera chief regulatory officer William Turner to retire, Nancy Boman to succeed
PremiumThe Fly
Vera chief regulatory officer William Turner to retire, Nancy Boman to succeed
2M ago
KYTX
VERA
Vera Therapeutics price target raised to $76 from $56 at Guggenheim
PremiumThe Fly
Vera Therapeutics price target raised to $76 from $56 at Guggenheim
2M ago
VERA
Vera Therapeutics price target raised to $78 from $73 at TD Cowen
PremiumThe FlyVera Therapeutics price target raised to $78 from $73 at TD Cowen
2M ago
VERA
Vera Therapeutics price target raised to $43 from $35 at Wedbush
Premium
The Fly
Vera Therapeutics price target raised to $43 from $35 at Wedbush
2M ago
VERA
FDA Approval and Extended Exclusivity of Trutakna Drive Vamil Divan to Reiterate Buy on Vera and Raise Price Target from $56 to $76
Premium
Ratings
FDA Approval and Extended Exclusivity of Trutakna Drive Vamil Divan to Reiterate Buy on Vera and Raise Price Target from $56 to $76
2M ago
VERA
Vera Therapeutics price target raised to $125 from $110 at H.C. Wainwright
PremiumThe Fly
Vera Therapeutics price target raised to $125 from $110 at H.C. Wainwright
2M ago
VERA
Maintaining a Buy on Vera: Commercial-Stage Transition and Trutakna Strength Support Unchanged $90 Price Target
PremiumRatings
Maintaining a Buy on Vera: Commercial-Stage Transition and Trutakna Strength Support Unchanged $90 Price Target
2M ago
VERA
Vera Therapeutics price target raised to $70 from $65 at BofA
PremiumThe Fly
Vera Therapeutics price target raised to $70 from $65 at BofA
2M ago
VERA
Vera Therapeutics gains FDA nod for TRUTAKNA launch
PremiumCompany Announcements
Vera Therapeutics gains FDA nod for TRUTAKNA launch
2M ago
8K
VERA
Vera’s Trutakna approved by FDA for adults with primary IgA nephropathy
PremiumThe FlyVera’s Trutakna approved by FDA for adults with primary IgA nephropathy
2M ago
VERA
Vera Therapeutics announces alignment with FDA on earlier ORIGIN 3 eGFR analysis
Premium
The Fly
Vera Therapeutics announces alignment with FDA on earlier ORIGIN 3 eGFR analysis
3M ago
VERA
Raymond James sees unique buying opportunity in Vera after FDA alignment
Premium
The Fly
Raymond James sees unique buying opportunity in Vera after FDA alignment
3M ago
VERA

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >